While a large body of evidence suggests that EGFR plays a significant role in GBM growth [4–6], previous efforts to target this receptor using EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have been unsuccessful [7]. This evidence concerns the gene EGFR and glioblastoma.